Robalzotan
Chemical compound / From Wikipedia, the free encyclopedia
Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A ligands was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H23FN2O2 |
Molar mass | 318.392 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close